Allogene Therapeutics (ALLO) Net Margin (2021 - 2024)
Allogene Therapeutics recorded quarterly Net Margin of 291231.82% in Q1 2024, up 22.43% quarter-over-quarter from 375447.62% in Q4 2023, and up 3221152.0% year-over-year from N/an in Q2 2023.
Allogene Therapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 291231.82% for Q1 2024.
- In Q1 2024, Net Margin rose 3221152.0% year-over-year to 291231.82%; the TTM figure through Dec 2024 stood at 1151031.82% (down 82531603.0% YoY), while the FY2024 annual figure was 1170863.64%, down 82637416.0% from the prior year.
- Net Margin came in at 291231.82% for Q1 2024 at Allogene Therapeutics, up from 375447.62% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 2.5% in Q4 2021 to a low of 375447.62% in Q4 2023.
- A 4-year average of 223087.67% and a median of 258140.91% in 2023 frame the typical range for Net Margin.
- Across the five-year window, Net Margin slumped 36014866 bps in 2022 and jumped 4374428 bps in 2023, its largest moves.
- Allogene Therapeutics' Net Margin stood at 2.5% in 2021, then tumbled by 14392819 bps to 360146.15% in 2022, then decreased by 4 bps to 375447.62% in 2023, then advanced by 22 bps to 291231.82% in 2024.
- According to Business Quant data, Net Margin over the past three periods registered 291231.82%, 375447.62%, and 258140.91% for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -291,231.82% |
| Dec 31, 2023 | -375,447.62% |
| Sep 30, 2023 | -258,140.91% |
| Jun 30, 2023 | -348,918.18% |
| Mar 31, 2023 | -323,443.33% |
| Dec 31, 2022 | -360,146.15% |
| Sep 30, 2022 | -301,885.19% |
| Jun 30, 2022 | -119,220.31% |
| Mar 31, 2022 | -203,902.56% |
| Dec 31, 2021 | 2.50% |
| Sep 30, 2021 | -157,708.16% |
| Jun 30, 2021 | -160,011.36% |
| Mar 31, 2021 | -86.58% |